看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 23.9x - 26.4x | 25.2x |
| Historical Pb Multiple | 10.2x - 54.5x | 25.5x |
| Fair Value | ₩36,729 - ₩40,595 | ₩38,662 |
| Upside | -6.2% - 3.7% | -1.2% |
| Benchmarks | - | Full Ticker |
| Oscotec Inc. | - | KOSDAQ:A039200 |
| Komipharm International Co., Ltd. | - | KOSDAQ:A041960 |
| Hanall Biopharma Co., Ltd. | - | KOSE:A009420 |
| ADBiotech Co., Ltd. | - | KOSDAQ:A179530 |
| WooGene B&G Co., Ltd | - | KOSDAQ:A018620 |
| Mezzion Pharma Co.,Ltd. | - | KOSDAQ:A140410 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | |||
| KOSDAQ:A039200 | KOSDAQ:A041960 | KOSE:A009420 | KOSDAQ:A179530 | KOSDAQ:A018620 | KOSDAQ:A140410 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 103.6% | 429.6% | -151.4% | -177.7% | -341.0% | -53.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -361.4% | -17.6% | 7.9% | -36.4% | -5.1% | -80.4% | ||
| Prior Fiscal Year | -490.4% | -9.3% | 2.6% | -27.3% | -2.0% | -40.1% | ||
| Latest Fiscal Year | 2.6% | 22.3% | -1.3% | -71.4% | -9.4% | -226.2% | ||
| Latest Twelve Months | 2.6% | 22.3% | -1.3% | -71.4% | -9.4% | -226.2% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -34.4% | -6.4% | 5.1% | -24.3% | -4.6% | -41.2% | ||
| Prior Fiscal Year | -21.9% | -6.8% | 2.0% | -19.4% | -3.4% | -29.0% | ||
| Latest Twelve Months | 0.8% | 22.1% | -1.0% | -87.2% | -17.0% | -36.2% | ||
| Next Fiscal Year | 9.7% | 9.9% | 3.2% | #NUM! | -69.4% | 151.8% | ||
| Two Fiscal Years Forward | 42.1% | 16.4% | 6.1% | -1313.1% | -226.4% | 70.1% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 30.8x | 6.9x | 10.3x | 1.8x | 0.5x | 136.4x | ||
| Price / LTM EPS | 1193.4x | 31.1x | -792.8x | -2.6x | -4.9x | -60.3x | ||
| Price / Book | 8.2x | 6.6x | 8.5x | 4.2x | 0.9x | 25.5x | ||
| Price / Fwd Book | 7.4x | 6.3x | 8.2x | 4.2x | 1.9x | 3.5x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.9x | 6.6x | 8.5x | |||||
| Historical P/B Ratio | 10.2x | 25.5x | 54.5x | |||||
| Selected P/B Multiple | 23.9x | 25.2x | 26.4x | |||||
| (x) Book Value | 46,063 | 46,063 | 46,063 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A039200 | A041960 | A009420 | A179530 | A018620 | A140410 | |
| Value of Common Equity | 1,046,088 | 407,999 | 1,430,869 | 20,515 | 25,450 | 1,174,787 | |
| (/) Shares Outstanding | 38.2 | 69.7 | 50.7 | 11.4 | 28.9 | 30.0 | |
| Implied Stock Price | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 27,350.00 | 5,850.00 | 28,200.00 | 1,806.00 | 881.00 | 39,150.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |